Phase I Study of Olaparib and Temozolomide in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy

Trial Profile

Phase I Study of Olaparib and Temozolomide in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 May 2017

At a glance

  • Drugs Irinotecan (Primary) ; Olaparib (Primary) ; Temozolomide (Primary)
  • Indications Ewing's sarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 09 May 2017 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
    • 09 May 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.
    • 03 Nov 2016 Irinotecan has been added to treatment schedule; Number of treatment arms changed from 1 to 2; Study design changed from single group to parallel group; Planned number of patients changed from 34 to 93; Time frame for primary endpoint changed from 2 years to 30 days.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top